Tanja Schlaikjær Hartwig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tanja Schlaikjær Hartwig has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Henriette Svarre Nielsen
Department of Obstetrics and Gynecology, The Fertility Clinic Copenhagen University Hospital Hvidovre Hvidovre Denmark
6 shared publications - David Westergaard
Department of Obstetrics and Gynaecology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
3 shared publications Finn Stener Jørgensen
Fetal Medicine Unit, Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, Denmark; Hvidovre Hospitals NIPT Center, Copenhagen University Hospital Hvidovre, Denmark
3 shared publications- Finn Stener Jørgensen
Faculty of Health and Medical Sciences, Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
3 shared publications - Steen Sørensen
Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Denmark
3 shared publications - Emily Koert
Section of Social Medicine, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
2 shared publications
Latest Publications
- 24 March 2026
- Published by Oxford University Press (OUP) in Human Reproduction
How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result?
How fast does cell-free fetal DNA (cffDNA) decline after early pregnancy loss and which factors affect the decline? After pregnancy loss cffDNA declines gradually with detectable levels persisting up to 3 days post-tissue passage correlating with β-hCG decline. Postpartum clearance of cffDNA occurs within hours, but little is known about its decline following early pregnancy loss. Initial results from the Copenhagen Pregnancy Loss (COPL) study showed slower clearance in relation to pregnancy loss with detectable levels found up to 24 h after tissue passage. This prospective cohort study included 1463 women from the COPL cohort, enrolled between 12 November 2020 and 19 December 2022. Participants were divided into three groups based on sampling time: the standard group (samples collected before tissue passage), the delayed sample group (samples collected after tissue passage at maximum 24 h), and the repeated sample group (samples collected at multiple time points after medical and surgical treatment). Eligible women were 18 years old with a confirmed intrauterine pregnancy loss before 22 gestational weeks. Exclusion criteria included ectopic, molar, or unknown-location pregnancies and inability to consent. For the repeated sample group, additional exclusions were vaginal bleeding at diagnosis, anembryonic pregnancies, and opting for expectant management. Blood samples were analyzed for β-hCG and cffDNA, with fetal fraction measured using the sequencing-based fetal fraction (SeqFF) method. In the repeated sampling group, analyses were performed on Days 2 and 3 for surgically treated and Days 7 and 14 for medically treated. After pregnancy tissue passage, both cffDNA and β-hCG levels declined consistently over time with a corresponding increase in no-call rates. The decline in SeqFF following pregnancy loss occurred more gradually than the immediate clearance previously reported after delivery, remaining measurable for up to 3 days after pregnancy loss, though 30% of samples became inconclusive at this timepoint. The fetal fraction of cffDNA was highest when tissue remained in utero and declined significantly beyond 12-h post-passage (median 4.7% 12 h). The no call rate was 9.1% when the tissue was still in situ but increased to 27.1% in the 12- to 24-h post-passage group. Higher β-hCG levels correlated with increased odds of a conclusive cffDNA test (OR 1.30, 95% CI: 1.20–1.43, P < 0.001). β-hCG is accounting for 20% of the variability in fetal fraction measurements. Variability in the decline of cffDNA between groups reflects the differences in the timing of sampling and treatment approaches. The small size of the repeated sample group may limit the generalizability of the findings. Reliance on the SeqFF method introduces variability, as it may not perform consistently. Adjustment for key confounders including BMI, gestational age, type of pregnancy loss, and timing of sampling was performed, but residual confounding cannot be ruled out. As a non-invasive method, cffDNA testing offers critical genetic insights for couples facing time-sensitive reproductive decisions or those with recurrent pregnancy loss. The correlation between β-hCG and fetal fraction suggests β-hCG screening could optimize sequencing decisions. These findings support refining cffDNA diagnostics to enhance pregnancy loss evaluation and reproductive care. The study was funded by the Ole Kirks Foundation, the BioInnovation Institute Foundation (BII21SG1020554, NNF20SA0066125, and NNF15OC0016662), the Novo Nordisk Foundation (NNF22OC0077221 and NNF23OC0087269), and the A.P. Møller Foundation. The authors have declared their COI. N/A.
- 24 March 2026
- Published by Oxford University Press (OUP) in Human Reproduction
How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result?
How fast does cell-free fetal DNA (cffDNA) decline after early pregnancy loss and which factors affect the decline? After pregnancy loss cffDNA declines gradually with detectable levels persisting up to 3 days post-tissue passage correlating with β-hCG decline. Postpartum clearance of cffDNA occurs within hours, but little is known about its decline following early pregnancy loss. Initial results from the Copenhagen Pregnancy Loss (COPL) study showed slower clearance in relation to pregnancy loss with detectable levels found up to 24 h after tissue passage. This prospective cohort study included 1463 women from the COPL cohort, enrolled between 12 November 2020 and 19 December 2022. Participants were divided into three groups based on sampling time: the standard group (samples collected before tissue passage), the delayed sample group (samples collected after tissue passage at maximum 24 h), and the repeated sample group (samples collected at multiple time points after medical and surgical treatment). Eligible women were 18 years old with a confirmed intrauterine pregnancy loss before 22 gestational weeks. Exclusion criteria included ectopic, molar, or unknown-location pregnancies and inability to consent. For the repeated sample group, additional exclusions were vaginal bleeding at diagnosis, anembryonic pregnancies, and opting for expectant management. Blood samples were analyzed for β-hCG and cffDNA, with fetal fraction measured using the sequencing-based fetal fraction (SeqFF) method. In the repeated sampling group, analyses were performed on Days 2 and 3 for surgically treated and Days 7 and 14 for medically treated. After pregnancy tissue passage, both cffDNA and β-hCG levels declined consistently over time with a corresponding increase in no-call rates. The decline in SeqFF following pregnancy loss occurred more gradually than the immediate clearance previously reported after delivery, remaining measurable for up to 3 days after pregnancy loss, though 30% of samples became inconclusive at this timepoint. The fetal fraction of cffDNA was highest when tissue remained in utero and declined significantly beyond 12-h post-passage (median 4.7% 12 h). The no call rate was 9.1% when the tissue was still in situ but increased to 27.1% in the 12- to 24-h post-passage group. Higher β-hCG levels correlated with increased odds of a conclusive cffDNA test (OR 1.30, 95% CI: 1.20–1.43, P < 0.001). β-hCG is accounting for 20% of the variability in fetal fraction measurements. Variability in the decline of cffDNA between groups reflects the differences in the timing of sampling and treatment approaches. The small size of the repeated sample group may limit the generalizability of the findings. Reliance on the SeqFF method introduces variability, as it may not perform consistently. Adjustment for key confounders including BMI, gestational age, type of pregnancy loss, and timing of sampling was performed, but residual confounding cannot be ruled out. As a non-invasive method, cffDNA testing offers critical genetic insights for couples facing time-sensitive reproductive decisions or those with recurrent pregnancy loss. The correlation between β-hCG and fetal fraction suggests β-hCG screening could optimize sequencing decisions. These findings support refining cffDNA diagnostics to enhance pregnancy loss evaluation and reproductive care. The study was funded by the Ole Kirks Foundation, the BioInnovation Institute Foundation (BII21SG1020554, NNF20SA0066125, and NNF15OC0016662), the Novo Nordisk Foundation (NNF22OC0077221 and NNF23OC0087269), and the A.P. Møller Foundation. The authors have declared their COI. N/A.
- Open Access
- 5 June 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-17
Systematic description of the development of a complex health intervention of information and support in a new pregnancy after pregnancy loss
In this paper, we present a systematic description of the development method of a complex health intervention (PREGAFTERPL) for couples with prior pregnancy loss (PL) to provide information and support in a new pregnancy using co-production and prototyping. A three-stage method described by Hawkins et al. and informed by O’Cathain et al. was tested to develop the PREGAFTERPL intervention for couples over a 24 month period. We used a combination of the partnership and theory and evidence based approaches of O’Cathain’s nine categories of intervention development approaches. The stages included: (1) Evidence review, needs assessment and stakeholder consultation, (2) Co-production with stakeholders (health care professionals, researchers and couples with prior pregnancy loss) via consultations and focus groups, and (3) Prototyping using focus group and online survey. The three stage co-production and prototyping process was iterative and cumulative with refinements occurring at each stage before progressing to the next stage. Using the three-stage method we co-produced and prototype-tested the intervention content and delivery methods for the PREGAFTERPL intervention. In stage 1 we identified the needs of pregnant women and their partners and potential content of the intervention to include information, coping strategies and tools and resources. In stage 2, multiple refinements of the content and delivery resulted from an action research cycle with input from stakeholders including the decision to divide the tool into one for women and another for partners. Initial prototyping in stage 3 showed that the tools were acceptable, useful and relevant and it was suitable to proceed with full-scale feasibility testing, implementation and evaluation. This framework presented in the PREGAFTERPL case study provides a practical example on how to co-produce and prototype a complex healthcare intervention in collaboration with key stakeholders including health care professionals and couples with prior pregnancy loss in order to meet an unmet need for information and support in a new pregnancy after PL. Through such case study, we hope that future researchers will be inspired to include co-production in their own intervention development projects by seeing that it is valuable and can be feasible and done with limited resources. Not applicable.
- 5 June 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-17
Open AccessSystematic description of the development of a complex health intervention of information and support in a new pregnancy after pregnancy loss
In this paper, we present a systematic description of the development method of a complex health intervention (PREGAFTERPL) for couples with prior pregnancy loss (PL) to provide information and support in a new pregnancy using co-production and prototyping. A three-stage method described by Hawkins et al. and informed by O’Cathain et al. was tested to develop the PREGAFTERPL intervention for couples over a 24 month period. We used a combination of the partnership and theory and evidence based approaches of O’Cathain’s nine categories of intervention development approaches. The stages included: (1) Evidence review, needs assessment and stakeholder consultation, (2) Co-production with stakeholders (health care professionals, researchers and couples with prior pregnancy loss) via consultations and focus groups, and (3) Prototyping using focus group and online survey. The three stage co-production and prototyping process was iterative and cumulative with refinements occurring at each stage before progressing to the next stage. Using the three-stage method we co-produced and prototype-tested the intervention content and delivery methods for the PREGAFTERPL intervention. In stage 1 we identified the needs of pregnant women and their partners and potential content of the intervention to include information, coping strategies and tools and resources. In stage 2, multiple refinements of the content and delivery resulted from an action research cycle with input from stakeholders including the decision to divide the tool into one for women and another for partners. Initial prototyping in stage 3 showed that the tools were acceptable, useful and relevant and it was suitable to proceed with full-scale feasibility testing, implementation and evaluation. This framework presented in the PREGAFTERPL case study provides a practical example on how to co-produce and prototype a complex healthcare intervention in collaboration with key stakeholders including health care professionals and couples with prior pregnancy loss in order to meet an unmet need for information and support in a new pregnancy after PL. Through such case study, we hope that future researchers will be inspired to include co-production in their own intervention development projects by seeing that it is valuable and can be feasible and done with limited resources. Not applicable.
- Open Access
Vaginal Microbiota Transplantation (VMT) for treatment of vaginal dysbiosis without the use of antibiotics – A Double-Blinded Randomized Controlled Trial in healthy women with vaginal dysbiosis
Here we describe the first double-blinded, randomized, placebo-controlled trial (RCT) on vaginal microbiota transplantation (VMT) without antibiotics in women with both symptomatic and asymptomatic vaginal dysbiosis. Forty-nine women were randomly assigned to VMT or placebo. The trial did not show a significant conversion to our predefined Lactobacillus -dominated microbiome. However, in participants not initially converting, antiseptic pretreatment before a subsequent VMT led to a 50% conversion rate, associated with an anti-inflammatory shift in gene expression. Metagenomic sequencing and strain-level genetic analysis confirmed donor engraftment in five of 10 women who showed microbiome conversion. Extensive exploration of the microbiome, immune response and metadata revealed differences in baseline energy metabolism in participants who later experienced donor engraftment. Treatments for vaginal dysbiosis are urgently needed and given that VMT can lead to donor engraftment and change the vaginal immune profile, future studies should focus on optimizing this treatment for various women’s health diseases.
Open AccessVaginal Microbiota Transplantation (VMT) for treatment of vaginal dysbiosis without the use of antibiotics – A Double-Blinded Randomized Controlled Trial in healthy women with vaginal dysbiosis
Here we describe the first double-blinded, randomized, placebo-controlled trial (RCT) on vaginal microbiota transplantation (VMT) without antibiotics in women with both symptomatic and asymptomatic vaginal dysbiosis. Forty-nine women were randomly assigned to VMT or placebo. The trial did not show a significant conversion to our predefined Lactobacillus -dominated microbiome. However, in participants not initially converting, antiseptic pretreatment before a subsequent VMT led to a 50% conversion rate, associated with an anti-inflammatory shift in gene expression. Metagenomic sequencing and strain-level genetic analysis confirmed donor engraftment in five of 10 women who showed microbiome conversion. Extensive exploration of the microbiome, immune response and metadata revealed differences in baseline energy metabolism in participants who later experienced donor engraftment. Treatments for vaginal dysbiosis are urgently needed and given that VMT can lead to donor engraftment and change the vaginal immune profile, future studies should focus on optimizing this treatment for various women’s health diseases.
- Open Access
Hydroxychloroquine treatment for recurrent pregnancy loss: a study protocol for a randomized, double-blind, placebo-controlled trial
Introduction Pregnancy loss occurs in 25% of all pregnancies. While 50-60% of the pregnancy losses are due to fetal chromosomal and structural abnormalities, incompatible with life, some of the remaining euploid pregnancy losses are likely caused by maternal conditions. At least 2% of all women suffer ≥3 consecutive pregnancy losses, defined as recurrent pregnancy loss (RPL). A hyperactive maternal immune system has been suspected to be responsible for rejection of healthy fetuses and be the underlying cause for unexplained recurrent pregnancy loss. However, very sparsely evidence-based treatment is available. The anti-inflammatory immune modulatory effects of hydroxychloroquine (HCQ) and casuistic reports of live births by women with previous RPL after HCQ-treatment, have given rise to several hypothesizes for HCQs impact on RPL. In this multicenter randomized, double-blinded, placebo-controlled trial (db-RCT) we aim to uncover whether HCQ can increase the live birth rate (LBR) in women with RPL, thus laying the foundation for an evidence-based treatment to make a real difference for a much-overlooked group of patients. Methods and analysis We will assess HCQ treatment in women with a minimum of four consecutive unexplained pregnancy losses (or three pregnancy losses including a second trimester pregnancy loss), and monitor a potential difference in LBR among women allocated treatment with HCQ and placebo, without exclusion of any included patients (Intention to treat analysis) and with exclusion of those with ectopic pregnancy, pregnancy loss due to chromosome abnormalities, neglect of treatment, induced abortion or those who withdraw from the treatment earlier than the protocol dictates (per protocol analysis). Secondary outcome measures include comparison of the rate of perinatal complications in the intervention group to the placebo group and examination of inflammatory and immunological mechanisms in peripheral blood. We aim to include 186 patients in the db-RCT. In addition, we will in a sub-study with 10 women monitor metabolic activity measured by ultra-low dose FDG-PET/CT scans before and during pregnancy. Metabolic activity correlates with grade of inflammation and will be measured in the uterus and immune-related tissue such as bone marrow, spleen, thymus, and lymph nodes. Ethics and Dissemination The db-RCT including the PET/CT sub-study has been approved by The Regional Committee on Health Research Ethics, The Danish Medicines Agency, The Danish Data Protection Agency, and transferred to The Center for Data handling Capital Region of Denmark in May 2024. The trial conforms to good clinical practice guidelines (GCP) and has been registered at ClinicalTrials.gov (ClinicalTrials.gov ID NCT03305263). Findings will be disseminated through peer-reviewed journals and at professional conferences. Strengths and limitations of this study Assessment of HCQ treatment in women with RPL to potentially increase LBR. Assessment of the rate of perinatal outcomes associability with HCQ treatment. RPL trials so far have struggled to obtain pregnancy tissue from PL and if obtained been severely contaminated with maternal tissue. We will use circulating cell-free fetal DNA (cffDNA), isolated from maternal peripheral blood for fetal genetic diagnostics as we demonstrated feasible in our recent Lancet publication. Non-invasive monitoring of inflammation in the uterus before and during pregnancy by the means of ultra-low dose PET/CT scans.
Open AccessHydroxychloroquine treatment for recurrent pregnancy loss: a study protocol for a randomized, double-blind, placebo-controlled trial
Introduction Pregnancy loss occurs in 25% of all pregnancies. While 50-60% of the pregnancy losses are due to fetal chromosomal and structural abnormalities, incompatible with life, some of the remaining euploid pregnancy losses are likely caused by maternal conditions. At least 2% of all women suffer ≥3 consecutive pregnancy losses, defined as recurrent pregnancy loss (RPL). A hyperactive maternal immune system has been suspected to be responsible for rejection of healthy fetuses and be the underlying cause for unexplained recurrent pregnancy loss. However, very sparsely evidence-based treatment is available. The anti-inflammatory immune modulatory effects of hydroxychloroquine (HCQ) and casuistic reports of live births by women with previous RPL after HCQ-treatment, have given rise to several hypothesizes for HCQs impact on RPL. In this multicenter randomized, double-blinded, placebo-controlled trial (db-RCT) we aim to uncover whether HCQ can increase the live birth rate (LBR) in women with RPL, thus laying the foundation for an evidence-based treatment to make a real difference for a much-overlooked group of patients. Methods and analysis We will assess HCQ treatment in women with a minimum of four consecutive unexplained pregnancy losses (or three pregnancy losses including a second trimester pregnancy loss), and monitor a potential difference in LBR among women allocated treatment with HCQ and placebo, without exclusion of any included patients (Intention to treat analysis) and with exclusion of those with ectopic pregnancy, pregnancy loss due to chromosome abnormalities, neglect of treatment, induced abortion or those who withdraw from the treatment earlier than the protocol dictates (per protocol analysis). Secondary outcome measures include comparison of the rate of perinatal complications in the intervention group to the placebo group and examination of inflammatory and immunological mechanisms in peripheral blood. We aim to include 186 patients in the db-RCT. In addition, we will in a sub-study with 10 women monitor metabolic activity measured by ultra-low dose FDG-PET/CT scans before and during pregnancy. Metabolic activity correlates with grade of inflammation and will be measured in the uterus and immune-related tissue such as bone marrow, spleen, thymus, and lymph nodes. Ethics and Dissemination The db-RCT including the PET/CT sub-study has been approved by The Regional Committee on Health Research Ethics, The Danish Medicines Agency, The Danish Data Protection Agency, and transferred to The Center for Data handling Capital Region of Denmark in May 2024. The trial conforms to good clinical practice guidelines (GCP) and has been registered at ClinicalTrials.gov (ClinicalTrials.gov ID NCT03305263). Findings will be disseminated through peer-reviewed journals and at professional conferences. Strengths and limitations of this study Assessment of HCQ treatment in women with RPL to potentially increase LBR. Assessment of the rate of perinatal outcomes associability with HCQ treatment. RPL trials so far have struggled to obtain pregnancy tissue from PL and if obtained been severely contaminated with maternal tissue. We will use circulating cell-free fetal DNA (cffDNA), isolated from maternal peripheral blood for fetal genetic diagnostics as we demonstrated feasible in our recent Lancet publication. Non-invasive monitoring of inflammation in the uterus before and during pregnancy by the means of ultra-low dose PET/CT scans.
- Open Access
- 20 November 2023
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 103 (2) , 351-359
Maternal age and the risk of fetal aneuploidy: A nationwide cohort study of more than 500 000 singleton pregnancies in Denmark from 2008 to 2017
Introduction: In this register‐based study of pregnancies in Denmark, we assessed the associations between maternal age and the risk of fetal aneuploidies (trisomy 21, trisomy 18, trisomy 13, triploidy, monosomy X and other sex chromosome aberrations). Additionally, we aimed to disentangle the maternal age‐related effect on fetal aneuploidies by cases with translocation trisomies and mosaicisms.Material and methods: We followed a nationwide cohort of 542 375 singleton‐pregnant women attending first trimester screening in Denmark between 2008 and 2017 until delivery, miscarriage or termination of pregnancy. We used six maternal age categories and retrieved information on genetically confirmed aneuploidies of the fetus and infant from the national cytogenetic register.Results: We confirmed the known associations between advanced maternal age and higher risk of trisomy 21, 18, 13 and other sex chromosome aberrations, especially in women aged ≥35 years, whereas we found no age‐related associations with triploidy or monosomy X. Cases with translocation trisomies and mosaicisms did not influence the overall reported association between maternal age and aneuploidies.Conclusion: This study provides insight into the accurate risk of fetal aneuploidies that pregnant women of advanced ages encounter.
- 20 November 2023
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 103 (2) , 351-359
Open AccessMaternal age and the risk of fetal aneuploidy: A nationwide cohort study of more than 500 000 singleton pregnancies in Denmark from 2008 to 2017
Introduction: In this register‐based study of pregnancies in Denmark, we assessed the associations between maternal age and the risk of fetal aneuploidies (trisomy 21, trisomy 18, trisomy 13, triploidy, monosomy X and other sex chromosome aberrations). Additionally, we aimed to disentangle the maternal age‐related effect on fetal aneuploidies by cases with translocation trisomies and mosaicisms.Material and methods: We followed a nationwide cohort of 542 375 singleton‐pregnant women attending first trimester screening in Denmark between 2008 and 2017 until delivery, miscarriage or termination of pregnancy. We used six maternal age categories and retrieved information on genetically confirmed aneuploidies of the fetus and infant from the national cytogenetic register.Results: We confirmed the known associations between advanced maternal age and higher risk of trisomy 21, 18, 13 and other sex chromosome aberrations, especially in women aged ≥35 years, whereas we found no age‐related associations with triploidy or monosomy X. Cases with translocation trisomies and mosaicisms did not influence the overall reported association between maternal age and aneuploidies.Conclusion: This study provides insight into the accurate risk of fetal aneuploidies that pregnant women of advanced ages encounter.
- Open Access
- 1 January 2023
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2023 (3) , hoad032
‘You’re never pregnant in the same way again’: prior early pregnancy loss influences need for health care and support in subsequent pregnancy
What are couples’ needs for health care and support in a subsequent pregnancy after prior early pregnancy loss (PL) and how do needs change across the pregnancy? Couples described unmet needs for pregnancy care in the first 20 weeks of pregnancy and were more satisfied with the care provided during the remainder of the pregnancy. Despite early PL being common (∼25% of pregnancies), there is a paucity of research to guide practice to optimize treatment and support future pregnancies. There has been low priority for the issue in research and a pervasive acceptance that couples should ‘just try again’ after experiencing PL. Women with prior PL report increased anxiety during the first trimester of pregnancy compared to those without previous PL. No longitudinal studies explore what couples’ needs are throughout the pregnancy and how these needs shift across time. This was a qualitative longitudinal dyadic (joint) interview study. In total, 15 couples who were pregnant after a prior PL were interviewed four times over their pregnancy. Couples were recruited from the Copenhagen Pregnancy Loss Cohort Research Programme. Interviews were held in person at the hospital or university, or online. Interviews ranged from 20 to 91 min (mean = 54 min). Inclusion criteria included couples with one to two prior early PL(s) who self-reported a new pregnancy and were willing to be interviewed together and in English. Couples were interviewed four times: after a positive pregnancy test and once in each trimester. Interviews were transcribed and data were analysed using thematic analysis to compare and contrast needs of the couples at each of the four time periods in the pregnancy and across the entire pregnancy. One same-sex couple and 14 heterosexual couples participated. Couples’ needs were categorized into two main longitudinal themes across the pregnancy, divided by the 20-week scan. Within each longitudinal theme, there were two themes to represent each time period. In the longitudinal theme ‘The first 20 weeks: a ‘scary’ gap in care’ there were two themes: Positive pregnancy test: ‘Tell them it’s not the same pregnancy’ and First trimester: ‘We craved that someone was taking care of us’. The standard pregnancy care offered in the public healthcare system in Denmark includes a scan at 12 and 20 weeks. While all couples wished for additional access to scans and monitoring of the foetus in early pregnancy to provide reassurance and detect problems early, they described considerable variation in the referrals and care they were offered. Both partners expressed a high degree of worry and anxiety about the pregnancy, with pregnant women in particular describing ‘surviv[ing] from scan to scan’ in the early weeks. Couples took scans wherever offered or paid for comfort scans, but this resulted in fragmented care. Instead, they wished for continuity in care, and acknowledgement and sensitivity that a pregnancy after PL is not the same as a first pregnancy. In the longitudinal theme ‘The second 20 weeks: Safety in the care system’ there were two themes: Second trimester: ‘I think we are in good hands’ and Third trimester: ‘It’s more of a ‘nice to know’ everything is OK than a ‘need to know’. Couples reported their distress was lower and overall needs for care were met during this time. They expressed general satisfaction with regular or extended antenatal support although, as in the first 20 weeks, additional acknowledgement and sensitivity regarding their history of PL was desired. Couples said they felt more secure given that they had access to a 24-hour telephone support by midwife/nurse if they had any concerns or questions. Participants were self-selected from an ongoing cohort study of patients presenting at hospital with PL. Single women were not included in the study. This study was limited to data collection in Denmark; however, other countries with public healthcare systems may have similar offerings with regard to their provision of antenatal care, care provided in recurrent pregnancy loss (RPL) clinics and the availability of private scans. The findings underscore that an early PL creates an increased need for monitoring and care in a subsequent pregnancy. This study highlights a gap in pregnancy care for those with a history of PL given that their need for monitoring and support is high in the early weeks of a new pregnancy before they have access to antenatal care, and before they have had multiple PLs and can be referred to the RPL unit. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101028172 for E.K. The Copenhagen Pregnancy Loss Cohort is funded by a grant from the BioInnovation Institute Foundation. H.S.N. has received scientific grants from Freya Biosciences, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordisk Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond, and Independent Research Fund Denmark. H.S.N. received personal payment or honoraria for lectures and presentations from Ferring Pharmaceuticals, Merck, Astra Zeneca, Cook Medical, Gedeon Richter, and Ibsa Nordic. All other authors declare no competing interests.
- 1 January 2023
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2023 (3) , hoad032
Open Access‘You’re never pregnant in the same way again’: prior early pregnancy loss influences need for health care and support in subsequent pregnancy
What are couples’ needs for health care and support in a subsequent pregnancy after prior early pregnancy loss (PL) and how do needs change across the pregnancy? Couples described unmet needs for pregnancy care in the first 20 weeks of pregnancy and were more satisfied with the care provided during the remainder of the pregnancy. Despite early PL being common (∼25% of pregnancies), there is a paucity of research to guide practice to optimize treatment and support future pregnancies. There has been low priority for the issue in research and a pervasive acceptance that couples should ‘just try again’ after experiencing PL. Women with prior PL report increased anxiety during the first trimester of pregnancy compared to those without previous PL. No longitudinal studies explore what couples’ needs are throughout the pregnancy and how these needs shift across time. This was a qualitative longitudinal dyadic (joint) interview study. In total, 15 couples who were pregnant after a prior PL were interviewed four times over their pregnancy. Couples were recruited from the Copenhagen Pregnancy Loss Cohort Research Programme. Interviews were held in person at the hospital or university, or online. Interviews ranged from 20 to 91 min (mean = 54 min). Inclusion criteria included couples with one to two prior early PL(s) who self-reported a new pregnancy and were willing to be interviewed together and in English. Couples were interviewed four times: after a positive pregnancy test and once in each trimester. Interviews were transcribed and data were analysed using thematic analysis to compare and contrast needs of the couples at each of the four time periods in the pregnancy and across the entire pregnancy. One same-sex couple and 14 heterosexual couples participated. Couples’ needs were categorized into two main longitudinal themes across the pregnancy, divided by the 20-week scan. Within each longitudinal theme, there were two themes to represent each time period. In the longitudinal theme ‘The first 20 weeks: a ‘scary’ gap in care’ there were two themes: Positive pregnancy test: ‘Tell them it’s not the same pregnancy’ and First trimester: ‘We craved that someone was taking care of us’. The standard pregnancy care offered in the public healthcare system in Denmark includes a scan at 12 and 20 weeks. While all couples wished for additional access to scans and monitoring of the foetus in early pregnancy to provide reassurance and detect problems early, they described considerable variation in the referrals and care they were offered. Both partners expressed a high degree of worry and anxiety about the pregnancy, with pregnant women in particular describing ‘surviv[ing] from scan to scan’ in the early weeks. Couples took scans wherever offered or paid for comfort scans, but this resulted in fragmented care. Instead, they wished for continuity in care, and acknowledgement and sensitivity that a pregnancy after PL is not the same as a first pregnancy. In the longitudinal theme ‘The second 20 weeks: Safety in the care system’ there were two themes: Second trimester: ‘I think we are in good hands’ and Third trimester: ‘It’s more of a ‘nice to know’ everything is OK than a ‘need to know’. Couples reported their distress was lower and overall needs for care were met during this time. They expressed general satisfaction with regular or extended antenatal support although, as in the first 20 weeks, additional acknowledgement and sensitivity regarding their history of PL was desired. Couples said they felt more secure given that they had access to a 24-hour telephone support by midwife/nurse if they had any concerns or questions. Participants were self-selected from an ongoing cohort study of patients presenting at hospital with PL. Single women were not included in the study. This study was limited to data collection in Denmark; however, other countries with public healthcare systems may have similar offerings with regard to their provision of antenatal care, care provided in recurrent pregnancy loss (RPL) clinics and the availability of private scans. The findings underscore that an early PL creates an increased need for monitoring and care in a subsequent pregnancy. This study highlights a gap in pregnancy care for those with a history of PL given that their need for monitoring and support is high in the early weeks of a new pregnancy before they have access to antenatal care, and before they have had multiple PLs and can be referred to the RPL unit. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101028172 for E.K. The Copenhagen Pregnancy Loss Cohort is funded by a grant from the BioInnovation Institute Foundation. H.S.N. has received scientific grants from Freya Biosciences, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordisk Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond, and Independent Research Fund Denmark. H.S.N. received personal payment or honoraria for lectures and presentations from Ferring Pharmaceuticals, Merck, Astra Zeneca, Cook Medical, Gedeon Richter, and Ibsa Nordic. All other authors declare no competing interests.
- 16 November 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 24 (12) , 889-899
Pregnancy Loss and Cardiovascular Diseases in Women: Recent Findings and Potential Mechanisms
Purpose of Review Pregnancy loss (PL) has been acknowledged by the American Heart Association as a risk factor for cardiovascular diseases (CVD) later in life. This review aims to sum up recent findings (< ~ 5 years), concerning the link between PL and CVD. Recent Findings The association between PL and risk of CVD increased with increasing number of PLs and is inversely correlated to maternal age, indicating that the association concerns euploid PLs. Likely mechanisms leading to PL and an increased risk of CVD include endothelial dysfunction, a pro-inflammatory state, antiphospholipid syndrome, autoimmunity, and genetic predisposition. Summary PL as an independent risk factor for CVD constitutes an obvious gateway for a more targeted approach to future research, prevention, and treatment. Future research should clarify the following questions to which the answers are still unknown: whether PL is (a) directly causing the increased risk of CVD or (b) sharing pathophysiological mechanisms also leading to CVD.
- 16 November 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 24 (12) , 889-899
Pregnancy Loss and Cardiovascular Diseases in Women: Recent Findings and Potential Mechanisms
Purpose of Review Pregnancy loss (PL) has been acknowledged by the American Heart Association as a risk factor for cardiovascular diseases (CVD) later in life. This review aims to sum up recent findings (< ~ 5 years), concerning the link between PL and CVD. Recent Findings The association between PL and risk of CVD increased with increasing number of PLs and is inversely correlated to maternal age, indicating that the association concerns euploid PLs. Likely mechanisms leading to PL and an increased risk of CVD include endothelial dysfunction, a pro-inflammatory state, antiphospholipid syndrome, autoimmunity, and genetic predisposition. Summary PL as an independent risk factor for CVD constitutes an obvious gateway for a more targeted approach to future research, prevention, and treatment. Future research should clarify the following questions to which the answers are still unknown: whether PL is (a) directly causing the increased risk of CVD or (b) sharing pathophysiological mechanisms also leading to CVD.
- 18 March 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (6) , 744-750
Noninvasive prenatal testing and maternal obesity: A review
Noninvasive prenatal testing (NIPT) has become a popular screening test for the most common fetal aneuploidies. The performance of NIPT is affected by several factors including maternal obesity, which results in a greater rate of no‐calls for obese pregnant women. Guidelines regarding NIPT in prenatal screening have been published, but with few and divergent recommendations on the issue. We aimed to review the medical literature, guidelines from scientific societies and information material from commercial NIPT providers on no‐calls and maternal obesity. We systematically identified medical literature and guidelines from scientific societies using the database MEDLINE. Information material from commercial NIPT providers was found via a systematic search on Google.com. Nine medical studies investigating the association between maternal obesity and NIPT no‐calls were included. They all showed the same trend: increasing no‐call rate with increasing maternal obesity. The no‐call rate ranged from 0% to 4.2% for women with body mass index (BMI) 18.5‐24.9 and from 5.4% to 70.1% for women BMI ≥40. We identified 17 scientific societies with guidelines and 13 commercial NIPT providers. All were checked for information material on no‐calls and maternal obesity. To allow comparison, all guidelines were examined to answer the same three predefined questions. Of the 17 included scientific societies, 13 (76.5%) mentioned the association between maternal obesity and NIPT no‐calls, two (11.8%) specified weight limits and three (17.6%) advised against NIPT for severely obese pregnant women. None of the 13 commercial NIPT providers provided specific recommendations, but four (30.8%) cite maternal obesity as a potential cause for a no‐call. Because of the increasing number of patients in this group, we advocate updated recommendations to guide decision making in prenatal screening for obese pregnant women.
- 18 March 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (6) , 744-750
Noninvasive prenatal testing and maternal obesity: A review
Noninvasive prenatal testing (NIPT) has become a popular screening test for the most common fetal aneuploidies. The performance of NIPT is affected by several factors including maternal obesity, which results in a greater rate of no‐calls for obese pregnant women. Guidelines regarding NIPT in prenatal screening have been published, but with few and divergent recommendations on the issue. We aimed to review the medical literature, guidelines from scientific societies and information material from commercial NIPT providers on no‐calls and maternal obesity. We systematically identified medical literature and guidelines from scientific societies using the database MEDLINE. Information material from commercial NIPT providers was found via a systematic search on Google.com. Nine medical studies investigating the association between maternal obesity and NIPT no‐calls were included. They all showed the same trend: increasing no‐call rate with increasing maternal obesity. The no‐call rate ranged from 0% to 4.2% for women with body mass index (BMI) 18.5‐24.9 and from 5.4% to 70.1% for women BMI ≥40. We identified 17 scientific societies with guidelines and 13 commercial NIPT providers. All were checked for information material on no‐calls and maternal obesity. To allow comparison, all guidelines were examined to answer the same three predefined questions. Of the 17 included scientific societies, 13 (76.5%) mentioned the association between maternal obesity and NIPT no‐calls, two (11.8%) specified weight limits and three (17.6%) advised against NIPT for severely obese pregnant women. None of the 13 commercial NIPT providers provided specific recommendations, but four (30.8%) cite maternal obesity as a potential cause for a no‐call. Because of the increasing number of patients in this group, we advocate updated recommendations to guide decision making in prenatal screening for obese pregnant women.
- 13 May 2019
- Published by Wiley in Prenatal Diagnosis
- Vol. 39 (8) , 635-642
High risk—What's next? A survey study on decisional conflict, regret, and satisfaction among high‐risk pregnant women making choices about further prenatal testing for fetal aneuploidy
Objectives: To investigate decision making among pregnant women when choosing between noninvasive prenatal testing, invasive testing, or no further testing.Methods: Women with a high‐risk result from the first trimester screening were invited to fill in two online questionnaires at gestational age 12 to 14 (Q1) and 24 weeks (Q2). The scales used were Decisional Conflict and Regret Scales, Satisfaction with genetic Counselling Scale, and Health‐Relevant Personality Inventory.Results: Three hundred thirty‐nine women agreed to participate, and the response rates were 76% on Q1 and 88% on Q2. A percentage of 75.4% chose an invasive test, 23.8% chose noninvasive prenatal testing (NIPT), 0.4% chose no further testing, and 0.4% had both NIPT and invasive testing. Among all participants, 13.3% had a high level of decisional conflict. We found that choosing NIPT was associated with a high decisional conflict (p = 0.013), receiving genetic counselling the same day was associated with a high decisional conflict (p = 0.039), and a high satisfaction with the genetic counselling was associated with low decisional conflict (p < 0.001). Furthermore, the personality subtrait “alexithymia” was associated with low decisional conflict (p = 0.043). There was a significant association between high decisional conflict and later decisional regret (p = 0.008).Conclusion: We present evidence that satisfaction with and timing of counselling are important factors to limit decisional conflict. Interestingly, women choosing NIPT had more decisional conflict than women choosing invasive testing.
- 13 May 2019
- Published by Wiley in Prenatal Diagnosis
- Vol. 39 (8) , 635-642
High risk—What's next? A survey study on decisional conflict, regret, and satisfaction among high‐risk pregnant women making choices about further prenatal testing for fetal aneuploidy
Objectives: To investigate decision making among pregnant women when choosing between noninvasive prenatal testing, invasive testing, or no further testing.Methods: Women with a high‐risk result from the first trimester screening were invited to fill in two online questionnaires at gestational age 12 to 14 (Q1) and 24 weeks (Q2). The scales used were Decisional Conflict and Regret Scales, Satisfaction with genetic Counselling Scale, and Health‐Relevant Personality Inventory.Results: Three hundred thirty‐nine women agreed to participate, and the response rates were 76% on Q1 and 88% on Q2. A percentage of 75.4% chose an invasive test, 23.8% chose noninvasive prenatal testing (NIPT), 0.4% chose no further testing, and 0.4% had both NIPT and invasive testing. Among all participants, 13.3% had a high level of decisional conflict. We found that choosing NIPT was associated with a high decisional conflict (p = 0.013), receiving genetic counselling the same day was associated with a high decisional conflict (p = 0.039), and a high satisfaction with the genetic counselling was associated with low decisional conflict (p < 0.001). Furthermore, the personality subtrait “alexithymia” was associated with low decisional conflict (p = 0.043). There was a significant association between high decisional conflict and later decisional regret (p = 0.008).Conclusion: We present evidence that satisfaction with and timing of counselling are important factors to limit decisional conflict. Interestingly, women choosing NIPT had more decisional conflict than women choosing invasive testing.